reports
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides ...
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% i...
Axogen, Inc. to report third quarter 2024 financial results and host c...
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the ...
Axogen Completes Submission of Biologics License Application to U.S. F...
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. “I am proud of the significant progress our team has made towards the regulatory transition o...
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing R...
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced today that it has granted an equity inducement award on September 3, 2024, to a new non-executive employee under the terms of the Axogen Inc.’s Inducement Equity Incentive Plan. The award was approved by the Compensation Committee of Axogen’s Board of Directors in accordance with NASDAQ Listing Rule...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLDN WILLDAN GROUP
VIRC VIRCO MANUFACTURING CORP.
TBBK THE BANCORP
PSIX POWER SOLUTIONS INTERNATIONAL INC.
NWPX NORTHWEST PIPE CO.
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS INC.
BFIN BANKFINANCIAL
AXGN AXOGEN INC.
ASPN ASPEN AEROGELS
MG/CN MAGNA INTERNATIONAL INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
GLOB GLOBANT SA
NGS NATURAL GAS SERVICES GROUP INC.
SGMS SCIENTIFIC GAMES CORPORATION
HRB H&R BLOCK INC.
MHH MASTECH DIGITAL
KINS KINGSTONE COS. INC.
FEIM FREQUENCY ELECTRONICS INC.
SIGA SIGA TECHNOLOGIES INC.
SNFCA SECURITY NATIONAL FINANCIAL CORP. CL A
PSNL PERSONALIS
VHI VALHI INC.
KLXE KLX ENERGY SERVICES
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
CLBT CELLEBRITE DI LTD
CINT CI&T INC
RKLB ROCKET LAB USA INC
PGRU PROPERTYGURU GROUP LTD
COHR COHERENT CORP
REAX ADL VENTURES INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
FIHL FIDELIS INSURANCE HOLDINGS LIMITED
LTH LIFE TIME GROUP HLDGS INC
ANG ANGLOGOLD ASHANTI LIMITED
HG HAMILTON INSURANCE GROUP LTD.
AKA AKA BRANDS HOLDING CORP
UBXG U BX TECHNOLOGY LTD
TEM TEMPUS AI INC
BVS BAYVIEW CAPITAL TRUST I PFD 9.76%
Axogen, Inc. Announces New Leadership Appointments
Axogen, Inc. Announces New Leadership Appointments The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective August 9, 2024 ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief execut...
Axogen, Inc. Reports Second Quarter 2024 Financial Results
Axogen, Inc. Reports Second Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased t...
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host ...
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conferen...
Company Reports Inducement Grants to Non-Executive New Employee Under ...
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. In connection with the commencement of employment on June 17, 2024, and as a material inducement of employment, an award was made under the Co...
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™ ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distribute...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leader...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold ind...
Axogen Inc. Initiates Rolling Submission of Biologics License Applicat...
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024. “Today’s milestone represents a signific...
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads C...
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, chief executive officer, and president, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on Wednesday, May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET. Webcast events can be accessed live through the page at . For...
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the sam...
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™ ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. “We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” said Karen Zaderej, chairman, CEO, and president. “We are ...
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host C...
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conferenc...
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Result...
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimates that revenues from ...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Res...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the co...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement of his employment on J...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospec...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve Cap demonstrated statistical superiority vs. standard-of-care neurectomy in the reduction of total pain reported by participants over the course of follow-up. ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.